Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing date is March 13, 2025, covering share purchases executed on March 12, 2025. The transaction was conducted through Citigroup Global Markets Limited as part of an existing share buyback programme under a non-discretionary agreement entered into on February 24, 2025.
Key Financial Metrics
- Shares Purchased (March 12, 2025): 755,000 ordinary shares.
- Price Range: Lowest price paid was 1,486.00 GBp; highest price paid was 1,519.00 GBp.
- Volume-Weighted Average Price (VWAP): 1,501.32 GBp.
- Trading Venue: London Stock Exchange (XLON).
- Programme Progress: Since February 24, 2025, the Company has purchased 9,016,042 ordinary shares.
- Treasury Shares Held: 178,086,345 ordinary shares.
- Shares in Issue (excluding Treasury): 4,137,102,996 ordinary shares.
- Total Voting Rights: 4,137,102,996.
Material Changes
The filing details a reduction in the number of shares in issue due to the purchase of 755,000 shares for treasury. The filing does not provide comparative financial data (revenue, profit, cash flow) for the period, as it is a disclosure of a specific capital transaction rather than a periodic financial report.
Guidance, Outlook, and Risks
The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. Specific risk factors are referenced as being described on pages 277 to 285 of the GSK 2024 Annual Report on Form 20-F. No new guidance or management commentary regarding operational outlook is provided in this document.
Investor Verification Checklist
- Verify the total number of shares purchased under the buyback programme since February 24, 2025 (stated as 9,016,042).
- Confirm the updated number of shares in issue (4,137,102,996) for calculating ownership percentages under Disclosure Guidance and Transparency Rules.
- Review the GSK 2024 Annual Report on Form 20-F (pages 277-285) for detailed risk factors referenced in the cautionary statement.
- Monitor future filings for updates on the remaining capacity or duration of the existing buyback programme.